Pfizer today won FDA approval for a new targeted drug for the treatment of relapsed or refractory acute lymphoblastic leukemia.
Martin Shkreli, who was convicted two weeks ago of federal criminal securities fraud, says he doesn’t think he will go to prison.
Valeant hit back against eye-device maker Icon in legal fight over proprietary lens technology.
Novo Nordisk, fighting competition to its blockbuster Victoza, just posted data on a follow-up drug that gives it an edge over archrival Trulicity.
Valeant says the situation is looking up at that Bausch + Lomb plant that has twice been responsible for Valeant receiving a CRL for a new eye drug.
A decade in biopharma has a way of featuring megablockbuster patent losses—and we mean mega, with a total $915B in lifetime sales.
If you’re looking for certainty in immuno-oncology, Bristol-Myers’ latest Opdivo-plus-Yervoy data won't help.
Biocon, which pulled its EU application for a Herceptin biosimilar because of manufacturing issues, expects to resubmit to authorities next quarter.
J&J chief Alex Gorsky bailed out of President Donald Trump's manufacturing council just as the president announced he would shut it down.
Facebook is the social media platform most pharma marketers plan to use in the next two years, followed by YouTube, LinkedIn and Twitter.